Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Nuria Sala González"'
Autor:
Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Raymond S. McDermott, Nuria Sala González, Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Eduardo Yanez, Yi-Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, Todd L. Saretsky, Sameer R. Ghate, Yi Cui, Jeri Kim, Evan Y. Yu
Publikováno v:
Journal of Clinical Oncology. 41:131-131
131 Background: The phase 3, randomized KEYLYNK-010 trial (NCT03834519) of pembro + ola vs next-generation hormonal agent (NHA) abi or enza did not significantly improve rPFS or OS in molecularly unselected pts with mCRPC treated with prior NHA and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::641e04550dc8efc695463a816411f7e7
https://doi.org/10.1200/jco.2023.41.6_suppl.131
https://doi.org/10.1200/jco.2023.41.6_suppl.131
Autor:
Josep Sabaté Ortega, Roser Fort Culillas, Marina Escoda Garcia, Carmen Amalia Vásquez-Dongo, Núria Sala González
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 7802-7809 (2023)
Cutaneous immune-related adverse events (cirAEs) are the most common side effects of immune checkpoint inhibitor (ICI) therapy (30–50% for all grades). The vast majority of them are low or mild and can be treated without ICI interruption. Autoimmun
Externí odkaz:
https://doaj.org/article/4abb8fe41cbb49e099b7e738d4bb1a52